No Data
No Data
Biodesix to Present New Data on the Nodify XL2 Test at ATS 2024 Annual Meeting
Data highlights ability of the Nodify XL2 test to identify benign nodules in patients with emphysema.
Biodesix Initiated at Buy by TD Cowen
Biodesix Initiated at Buy by TD Cowen
Biodesix (BDSX.US) was first covered by TD Cowen, which gave it a buy rating, with a target price of $2.80.
Biodesix (BDSX.US) was first covered by TD Cowen, which gave it a buy rating, with a target price of $2.80.
Biodesix Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/13/2024 68.67% TD Cowen → $2.8 Initiates Coverage On → Buy 05/03/2024 80.72% Lake Street → $3 Initiates
TD Cowen Starts Biodesix With Buy Rating, $2.80 Price Target
TD Cowen Starts Biodesix With Buy Rating, $2.80 Price Target.
Buy Rating Justified by Biodesix's Market Leadership and Strong Growth Prospects
No Data